All In Biotech

Drug Trial Radar · NCT00926835

Effect of Antidepressants on the Treatment for Korean Major Depressive Disorder Patients

A Study to Investigate the Effect of Antidepressants on the Treatment for Korean Major Depressive Disorder (MDD) Patients

Last checked: Nov 19, 2026Latest source record: Sep 2, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedPivotal-lookingRandomized with 692 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

692

Actual

Start

May 2009

Primary completion

May 2015

Study completion Jul 2015

Sponsor

Lead sponsor
Ministry of Health & Welfare, KoreaGovernment (non-federal)
Sponsor type
Government (non-federal)
First posted
Jun 24, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary purpose of this study is to investigate the effectiveness of antidepressants on the treatments for non-psychotic major depressive disorder (MDD) in Korea. The study divides MDD patients into 3 level groups according to their past histories to treatments and compares the effectiveness of various treatment regimens at each level. The treatment level groups are: 1) patients who have never been treated with appropriate medications for their current depressive symptoms before, 2) who received an appropriate SSRI (Selective Serotonin Reuptake Inhibitor) once but did not respond to it, 3) who received two types of SSRI antidepressant treatments without much effects in reducing their depressive symptoms. The first level group will be treated with a single SSRI antidepressant treatment. The second and third level groups, who received SSRI treatment before, will be treated with alternative SSRI antidepressants (switching), combined multiple SSRI treatments (antidepressant combination), or SSRI treatments combined with mood stabilizer or anti-psychotics (augmentation). This study does not use placebos. Patients will visit 5 times for 6 weeks at each level for treatments. Patients will be evaluated for the severity of depressive symptoms, functional level, and side effects at each visit. Afterwards, the investigations will combine to monitor the patients depressive symptoms in every 3 months for the next 24 months. 18 nationwide university hospitals will participate in this study. This multi-site, prospective, and naturalistic study for patients with depression in Korea is a main project of 'Clinical Research Center for Depression' funded by the Ministry for Health, Welfare, and Family Affairs (MIHWAF) in Korea for a highly-qualified research achievement.

Conditions

  • Major Depressive Disorder

Interventions

  • paroxetineDrug

    6 weeks, 20-50mg/day

  • EscitalopramDrug

    10-20mg/day for 6 weeks

  • Venlafaxine XRDrug

    Venlafaxine 75-225mg/day for 6 weeks

  • Paroxetine+BupropionDrug

    paroxetine 20-50mg/day + bupropion 150-400mg/day for 6 weeks

  • Paroxetine+LamotrigineDrug

    Paroxetine 20-50mg/day + lamotrigine 100-400mg/day for 6 weeks

  • Paroxetine+LithiumDrug

    Paroxetine 20-50mg/day + lithium 0.5-1.2 mEq/L

  • Escitalopram+MirtazapineDrug

    escitalopram 10-20mg/day + mirtazapine 15-45mg/day for 6 weeks

  • Escitalopram+AripiprazoleDrug

    escitalopram 10-20mg/day + aripiprazole 5-15mg/day for 6 weeks

  • Paroxetine + Venlafaxine XRDrug

    Paroxetine 20-50mg/day + Venlafaxine 75-225mg/day for 6 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Hamilton Depression Rating ScaleTime frame: 6 week

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Clinical research center for depression

    Seoul, Seoul, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.